Tirzepatide results: what the trial evidence shows

Last updated 2026-07-27

What does the research actually show tirzepatide does?

Tirzepatide is a once-weekly injectable that mimics two gut hormones, GLP-1 and GIP, which together slow stomach emptying, reduce appetite, and improve how the body handles insulin. It's sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Same molecule, same manufacturer (Eli Lilly), different FDA-approved indication and labeling ^[1][2]. The evidence base is unusually large for a newer drug. Two trial programs matter most: SURMOUNT (weight loss in adults with obesity or overweight) and SURPASS (blood sugar control in type 2 diabetes). Both ran multiple phase 3 trials with thousands of participants, published in the New England Journal of Medicine and The Lancet, and both led directly to FDA approval, first Mounjaro in May 2022, then Zepbound in November 2023 ^[1][2]. What sets tirzepatide apart from older GLP-1 drugs like semaglutide is the dual mechanism. GIP receptor activation appears to add metabolic benefit on top of GLP-1's appetite effects, which may explain why head-to-head-style comparisons have shown larger average weight loss with tirzepatide than with semaglutide. We don't yet have a single trial that randomized the two directly for weight loss. SURMOUNT and the semaglutide STEP trials are separate programs with different populations, so cross-trial comparisons carry real uncertainty.

How much weight do people actually lose on tirzepatide?

In SURMOUNT-1, the key weight-loss trial, adults without diabetes lost an average of 15% of body weight on the 5 mg dose, 19.5% on 10 mg, and 20.9% on the 15 mg (maximum) dose over 72 weeks, compared to 3.1% on placebo ^[3]. Nearly 57% of people on the highest dose lost at least 20% of their body weight; on placebo, that number was under 3% ^[3]. SURMOUNT-2, done specifically in adults with type 2 diabetes and obesity, showed smaller but still substantial losses: about 13.4% on 15 mg over 72 weeks, versus 3.3% on placebo ^[4]. People with diabetes tend to lose less weight than people without it on the same drug and dose. That pattern shows up across the whole GLP-1 class, more than tirzepatide. Some context on the FDA's own summary: the agency's Zepbound approval was built on "an average weight loss of 18% at the 5 mg dose, 21% at the 10 mg dose, and 22.5% at the 15 mg dose" compared to 2.4% with placebo in the trial population, at 72 weeks ^[2]. These are trial averages, not guarantees, and they came from people who also received counseling on diet and exercise as part of the study protocol, not the drug alone. | Trial | Population | Dose | Avg. weight loss (72 wk) | Placebo |

How does tirzepatide affect blood sugar and A1C in type 2 diabetes?

This is where tirzepatide has its oldest and deepest evidence base. Across the SURPASS program, tirzepatide lowered hemoglobin A1C by roughly 1.8 to 2.1 percentage points depending on dose and comparator, and a meaningful share of participants got their A1C under 5.7%, the threshold generally considered non-diabetic ^[1][5]. In SURPASS-2, tirzepatide was compared directly against semaglutide 1 mg (a standard GLP-1 dose at the time) in over 1,800 adults with type 2 diabetes. All three tirzepatide doses (5, 10, and 15 mg) beat semaglutide on both A1C reduction and weight loss at 40 weeks; the 15 mg group averaged an A1C reduction of about 2.3 percentage points versus about 1.86 for semaglutide, and lost more weight too ^[5]. That's one of the few times a head-to-head trial in this class has shown a clear separation between two active drugs rather than drug versus placebo. For context on the mechanism claim: Lilly and independent researchers describe tirzepatide as "the first and only approved GIP and GLP-1 receptor agonist" ^[1], which is the basis for calling it dual-acting rather than a straight GLP-1 drug like semaglutide or liraglutide.

How fast does tirzepatide work, and when do results plateau?

Don't expect much in week one or two. Appetite suppression and early weight change typically start showing up by weeks 4-8, and the SURMOUNT trials measured their headline results at 72 weeks (about 16-17 months), not at 3 months ^[3][4]. People chasing fast results often stop before the dose has been titrated high enough to matter. Dosing starts low (2.5 mg weekly) for four weeks specifically to reduce nausea, then increases in 2.5 mg increments roughly every four weeks up to a maintenance dose of 5, 10, or 15 mg, per the FDA label ^[6]. That titration schedule alone means it takes at least 12-20 weeks to reach a full maintenance dose if someone titrates all the way to 15 mg. If you're mapping out your own schedule, the Tirz Rx dosage guide and the Tirz Rx dosage calculator walk through the standard titration steps in more detail. Weight loss in the trials didn't fully plateau by 72 weeks either; the curves were still trending down modestly at the last measured point in SURMOUNT-1, which suggests some people may keep losing weight slowly beyond 72 weeks on a stable dose, though the trials didn't run indefinitely to confirm where the true plateau sits.

What happens if you stop tirzepatide? Does weight come back?

Largely, yes, for most people. The SURMOUNT-4 trial specifically tested this: participants took tirzepatide for 36 weeks, then were randomized to either continue the drug or switch to placebo for another 52 weeks. Those switched to placebo regained an average of 14 percentage points of body weight (from about -25.3% to roughly -9.9% relative to baseline), while those who stayed on tirzepatide continued losing, ending around -25.3% total from baseline maintained or improved ^[7]. This mirrors what's been shown with semaglutide (the STEP 4 trial found similar rebound) and fits the underlying biology: these drugs work by keeping appetite and satiety signaling changed, and that effect fades once the drug clears the body, roughly 5 weeks given tirzepatide's approximate half-life of about 5 days ^[6]. That's the honest, unglamorous part of this drug class. It behaves more like a blood pressure medication than a course of antibiotics: the benefit tracks with ongoing use. Anyone planning a defined stop point should read up on Tirz Rx cycle length before assuming results will hold.

What are the real side effects, according to the trials?

Gastrointestinal side effects are the headline, and they are common, not rare edge cases. Across SURMOUNT-1, nausea occurred in about 24-33% of participants depending on dose (versus about 10% on placebo), diarrhea in roughly 17-22%, constipation in around 12-17%, and vomiting in about 10-13% ^[3]. Most cases were described as mild to moderate and clustered during dose increases. Discontinuation due to side effects happened in about 4.3% to 7.1% of tirzepatide-treated participants across doses in SURMOUNT-1, compared with about 2.6% on placebo ^[3]. So most people who start don't quit from side effects, but a meaningful minority do. Beyond the GI symptoms, the FDA label for both Mounjaro and Zepbound carries a boxed warning about thyroid C-cell tumors seen in rodent studies; it's contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[6]. It's not known whether tirzepatide causes MTC in humans, but the signal in animal studies was strong enough that FDA required the warning and the contraindication rather than a softer caution. Other risks flagged in labeling and trial safety data include acute pancreatitis, gallbladder disease (including gallstones, sometimes requiring cholecystectomy), acute kidney injury (often secondary to dehydration from vomiting or diarrhea), and hypoglycemia when tirzepatide is combined with insulin or sulfonylureas ^[6]. Severe hypersensitivity reactions have also been reported. None of this is minor, and anyone with a history of pancreatitis or gallbladder disease should talk it through with a prescriber before starting.

How does tirzepatide compare to semaglutide (Ozempic/Wegovy) in the data?

The clearest direct comparison is SURPASS-2, described above, where tirzepatide beat semaglutide 1 mg on both A1C and weight in people with type 2 diabetes ^[5]. For weight loss specifically in people without diabetes, there isn't a completed trial that randomized tirzepatide against semaglutide 2.4 mg (the Wegovy dose) head-to-head; SURMOUNT and STEP are separate trial programs run years apart with different enrollment criteria, so any comparison of their topline numbers (SURMOUNT-1's ~20.9% at 15 mg vs. STEP 1's roughly 14.9% average weight loss at 68 weeks) is informative but not the same as a randomized comparison. A later trial, SURMOUNT-5, did directly compare tirzepatide to semaglutide 2.4 mg in adults with obesity without diabetes and found tirzepatide produced significantly greater weight loss at 72 weeks, though exact published percentages should be checked against the primary publication rather than repeated secondhand, since trial reporting details (percentage vs. absolute kg, intention-to-treat vs. per-protocol) affect the headline number meaningfully. The practical takeaway: tirzepatide's dual mechanism does appear to produce somewhat larger average weight loss in the populations studied so far, but individual response varies a lot, and "bigger average effect in a trial" doesn't mean it will be the better or better-tolerated choice for any one person.

Compounded tirzepatide vs. Mounjaro and Zepbound: what's actually different?

Mounjaro and Zepbound are FDA-approved, meaning every batch is manufactured under FDA-inspected conditions with verified purity, strength, and sterility, and every claim on the label is backed by the trial data cited throughout this article ^[1][2]. Compounded tirzepatide is a different regulatory category entirely: it's prepared by a compounding pharmacy, typically from bulk active pharmaceutical ingredient, and it is not FDA-approved, meaning it hasn't gone through the agency's own review of that specific product's manufacturing and quality. FDA allowed compounding of tirzepatide more widely during the period when Mounjaro and Zepbound were listed on the FDA's drug shortage list; once Lilly's supply caught up and FDA removed tirzepatide from that shortage list in late 2024, the legal basis for mass compounding narrowed considerably, and compounders are generally restricted to filling patient-specific prescriptions rather than bulk production, under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. None of the SURMOUNT or SURPASS trial data was generated using compounded product; it was all done with Lilly's manufactured tirzepatide. That doesn't mean compounded tirzepatide can't work pharmacologically, since it's the same molecule if made correctly. But it does mean the specific percentages and safety profile from these trials formally apply to the FDA-approved product, not to any given compounding pharmacy's output, which can vary in purity and concentration depending on the source and process. If you're using a compounded version, the practical steps around how to reconstitute Tirz Rx, Tirz Rx how to inject, and Tirz Rx injection sites matter more, since dosing accuracy depends on the person, not a pre-filled pen.

Who was actually studied in these trials, and who wasn't?

SURMOUNT-1 enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (like hypertension or high cholesterol), and excluded people with type 1 or type 2 diabetes from that specific trial ^[3]. SURMOUNT-2 specifically studied people with both obesity and type 2 diabetes ^[4]. SURPASS trials enrolled adults with type 2 diabetes, with varying A1C entry thresholds and background medication use across the different sub-trials ^[1][5]. Pregnant people, people under 18, and people with a personal or family history of MTC/MEN 2 were excluded across the program, consistent with the label's contraindications ^[6]. Trial populations also skewed toward participants recruited through clinical trial sites in specific countries and health systems, which is worth remembering: results in a broader, more diverse real-world population, including people managing multiple chronic conditions or taking many other medications, may look somewhat different from the tightly controlled trial cohorts. This matters for anyone reading the headline percentages and assuming they'll get exactly that number. Average trial results describe a population, not a person; individual results in these trials ranged widely around those averages.

What don't we know yet?

Long-term data beyond about 3 years is still thin. Most of the key trials ran 40 to 72 weeks, with some extension data pushing past a year, but we don't have the kind of multi-decade safety data that exists for older drug classes. Cardiovascular outcomes data is still maturing. Tirzepatide has cardiovascular outcomes trials underway and reported (SURPASS-CVOT and related work), but the strength and breadth of that evidence isn't yet at the level of the long-established GLP-1 cardiovascular outcome trials for semaglutide and liraglutide, so anyone choosing based specifically on heart-protective effect should look at what's currently published rather than assume equivalence across the class. And real-world adherence and long-term weight maintenance outside of trial conditions (with dietitian support, structured follow-up, and free study drug) is genuinely uncertain. Trial retention and monitoring don't match typical clinical practice, and that gap probably explains at least some of the difference between headline trial percentages and what people report anecdotally.

How should someone use this evidence to make a decision?

Start with your own numbers and health history, not the trial average. If your BMI and comorbidity profile roughly matches the SURMOUNT-1 population, the 15-20% range at maintenance dose over about a year and a half is a reasonable expectation, not a promise. If you have type 2 diabetes, expect somewhat less weight loss but still meaningful A1C improvement, in the same ballpark as SURPASS-2's roughly 2-point reduction ^[5]. Take the boxed warning seriously if you have any personal or family history of thyroid cancer syndromes; that's a hard contraindication, not a soft caution ^[6]. Expect nausea and GI symptoms during dose increases, and don't judge the drug's effect on your body from week one. A provider-reviewed process matters here, more than it might for a lower-risk medication, because dose titration, contraindication screening, and side-effect management all benefit from someone actually looking at your labs and history rather than a generic protocol. Tirz Rx connects that provider review to fulfillment through its pharmacy partner, which is the more sensible path than trying to self-diagnose dosing off a spreadsheet.

Where can I read the primary trial data myself?

If you want to check any of the numbers above against the source rather than take a summary's word for it, start with the New England Journal of Medicine's SURMOUNT-1 publication ^[3] and the FDA's own approval summaries for Mounjaro and Zepbound ^[1][2], which include the prescribing information with full boxed warnings, contraindications, and adverse event tables ^[6]. The Lancet's SURPASS-2 publication ^[5] has the most direct head-to-head numbers against semaglutide. ClinicalTrials.gov listings for NCT04184622 (SURMOUNT-1) and NCT03987919 (SURPASS-2) let you see the original trial design, enrollment criteria, and outcome measures as registered before results came in, which is a useful check against selective reporting.

Frequently asked questions

How much weight can you realistically lose on tirzepatide?

In SURMOUNT-1, average losses at 72 weeks were 15% of body weight at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to 3.1% on placebo. Individual results vary widely around these averages; some people lose much more, others less, depending on dose, adherence, and starting weight.

Does tirzepatide work better than Ozempic or Wegovy?

In SURPASS-2, tirzepatide beat semaglutide 1 mg on both A1C reduction and weight loss in people with type 2 diabetes. For pure weight loss without diabetes, SURMOUNT and STEP trial programs weren't directly randomized against each other in most cases, though SURMOUNT-5 did compare tirzepatide directly to semaglutide 2.4 mg and found greater weight loss with tirzepatide.

How long does it take tirzepatide to start working?

Some appetite suppression starts within weeks, but the trials measured headline results at 72 weeks. Dose titration alone takes 12-20 weeks to reach a full maintenance dose of 15 mg, since increases happen in 2.5 mg steps roughly every four weeks to limit nausea.

What happens if you stop taking tirzepatide?

SURMOUNT-4 found that people who switched from tirzepatide to placebo after 36 weeks regained about 14 percentage points of body weight over the next year, while those who continued the drug kept losing or maintained. Weight regain after stopping is the norm, not the exception, in this trial data.

What are the most common tirzepatide side effects in trials?

Nausea (24-33%), diarrhea (17-22%), constipation (12-17%), and vomiting (10-13%) were the most common in SURMOUNT-1, versus roughly 10% nausea on placebo. Most were mild to moderate and occurred during dose increases; 4.3% to 7.1% of participants stopped the drug due to side effects.

Is tirzepatide safe for the thyroid or gallbladder?

Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies and is contraindicated in anyone with personal or family history of medullary thyroid carcinoma or MEN 2. Gallbladder disease, including gallstones, was also reported in trials and is listed as a risk in labeling.

What's the difference between Mounjaro and Zepbound?

Both contain tirzepatide, made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes (approved May 2022); Zepbound is FDA-approved for chronic weight management (approved November 2023). Doses and labeling differ slightly by indication, but the underlying drug is identical.

Does compounded tirzepatide have the same trial evidence behind it?

No. SURMOUNT and SURPASS trials used Lilly's FDA-approved manufactured tirzepatide, not compounded product. Compounded tirzepatide is the same molecule if made correctly, but it hasn't been reviewed by FDA as a specific manufactured product, and purity or concentration can vary by compounding source.

How much does A1C drop with tirzepatide in diabetes trials?

Across SURPASS trials, A1C reductions ranged roughly 1.8 to 2.1 percentage points depending on dose and comparator. In SURPASS-2, the 15 mg dose reduced A1C by about 2.3 points versus about 1.86 points for semaglutide 1 mg over 40 weeks.

Who was excluded from the tirzepatide trials?

Pregnant people, those under 18, and anyone with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 were excluded across the program. SURMOUNT-1 excluded people with diabetes; SURPASS trials specifically required a type 2 diabetes diagnosis.

Does tirzepatide help with conditions besides weight and blood sugar?

Research is ongoing into effects on conditions linked to obesity and metabolic disease, including obstructive sleep apnea and certain cardiovascular risk markers, with cardiovascular outcomes trials still maturing. As of now, FDA approval covers only type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

How many people in the trials lost 20% or more of their body weight?

In SURMOUNT-1, about 57% of participants on the 15 mg dose lost at least 20% of body weight by 72 weeks, compared to under 3% on placebo. This was one of the largest proportions achieving that threshold of any weight-loss drug trial published to date.

Sources

1. FDA, Zepbound (tirzepatide) approval announcement: Zepbound was FDA-approved for chronic weight management in November 2023, with average weight loss of 18-22.5% across doses in trials
2. New England Journal of Medicine, SURMOUNT-1 trial results: Average weight loss of 15%, 19.5%, and 20.9% at 5, 10, and 15 mg doses over 72 weeks, versus 3.1% on placebo, with side effect and discontinuation rates
3. The Lancet, SURMOUNT-2 trial results: Average weight loss of about 13.4% at 15 mg over 72 weeks in adults with obesity and type 2 diabetes, versus 3.3% on placebo
4. The Lancet, SURPASS-2 trial results: Head-to-head comparison showing tirzepatide outperformed semaglutide 1 mg on A1C reduction and weight loss over 40 weeks
5. FDA, Zepbound prescribing information (label): Boxed warning for thyroid C-cell tumors, contraindications for MTC/MEN 2 history, dosing titration schedule, and adverse reaction tables
6. ClinicalTrials.gov, SURMOUNT-4 trial record and results: Participants switched to placebo after 36 weeks of tirzepatide regained substantial weight over the following year compared to those who continued treatment
7. ClinicalTrials.gov, SURMOUNT-1 trial registration: Original trial design, enrollment criteria (BMI 30+, or 27+ with comorbidity, no diabetes), and outcome measures for SURMOUNT-1
8. ClinicalTrials.gov, SURPASS-2 trial registration: Original trial design and enrollment criteria for the head-to-head tirzepatide vs. semaglutide trial in type 2 diabetes